{{Drugbox
| Watchedfields = changed
| verifiedrevid = 447573683
| IUPAC_name = methyl 7-[(1''S'',2''S'',3''S'')-3-hydroxy-2-[(3''R'')-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate
| image = Enprostil.svg
| width = 240

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|enprostil}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 73121-56-9
| ATC_prefix = A02
| ATC_suffix = BB02
|  PubChem = 5311225
|  ChemSpiderID = 4470744
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J4IP5Z9DAU
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01891

<!--Chemical data-->
| C=23 | H=28 | O=6 
| molecular_weight = 400.46 g/mol
| smiles            = COC(=O)CCC=C=CC[C@@H]1[C@H]([C@@H](CC1=O)O)/C=C/[C@H](COc2ccccc2)O
| StdInChI          = 1S/C23H28O6/c1-28-23(27)12-8-3-2-7-11-19-20(22(26)15-21(19)25)14-13-17(24)16-29-18-9-5-4-6-10-18/h3-7,9-10,13-14,17,19-20,22,24,26H,8,11-12,15-16H2,1H3/b14-13+/t2?,17-,19-,20-,22-/m1/s1
| StdInChIKey       = PTOJVMZPWPAXER-VFJVYMGBSA-N
}}
'''Enprostil''' is a synthetic [[prostaglandin]] designed to resemble [[dinoprostone]]. Enprostil was found to be a highly potent inhibitor of gastric HCl secretion.<ref>{{cite journal |pmid=3095537 |year=1986 |last1=Roszkowski |first1=AP |last2=Garay |first2=GL |last3=Baker |first3=S |last4=Schuler |first4=M |last5=Carter |first5=H |title=Gastric antisecretory and antiulcer properties of enprostil, (+/−)-11 alpha, 15 alpha-dihydroxy-16-phenoxy-17,18,19,20-tetranor-9-oxoprosta-4,5,13(t)-trienoic acid methyl ester |volume=239 |issue=2 |pages=382–9 |journal=The Journal of Pharmacology and Experimental Therapeutics}}</ref> It is an analog of [[prostaglandin E2]] but unlike this prostaglandin, which binds to and activates all four cellular [[Receptor (biochemistry)|receptors]] viz., [[Prostaglandin EP1 receptor|EP1]], [[Prostaglandin EP2 receptor|EP2]], [[Prostaglandin EP3 receptor|EP3]], and [[Prostaglandin EP4 receptor|EP4]] receptors, enprostil is a more selective [[receptor agonist]] in that it binds to and activates primarily the EP3 receptor.<ref name="pmid27940058">{{cite journal | vauthors = Moreno JJ | title = Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis | journal = European Journal of Pharmacology | volume = 796 | issue = | pages = 7–19 | year = 2017 | pmid = 27940058 | doi = 10.1016/j.ejphar.2016.12.004 | url = }}</ref> Consequently, enprostil is expected to have a narrower range of actions that may avoid some of the unwanted side-effects and toxicities of prostaglandin E2. A prospective multicenter randomized controlled trial conducted in Japan found combining enprostil with cimetidine was more effective than cimetidine alone in treating gastric ulcer.<ref name="pmid16334808">{{cite journal | vauthors = Murata H, Kawano S, Tsuji S, Tsujii M, Hori M, Kamada T, Matsuzawa Y, Katsu K, Inoue K, Kobayashi K, Mitsufuji S, Bamba T, Kawasaki H, Kajiyama G, Umegaki E, Inoue M, Saito I | title = Combination of enprostil and cimetidine is more effective than cimetidine alone in treating gastric ulcer: prospective multicenter randomized controlled trial | journal = Hepato-gastroenterology | volume = 52 | issue = 66 | pages = 1925–9 | year = 2005 | pmid = 16334808 | doi = | url = }}</ref>

==See also==
*[[Prostaglandin receptors]]
*[[Prostaglandin EP3 receptor#digestive system|EP3 and peptic ulcer]] 

==References==
{{reflist}}

==External links==
* {{cite journal |doi=10.1046/j.1365-3083.2000.00815.x |title=Enprostil, a Prostaglandin-E2 Analogue, Inhibits Interleukin-8 Production of Human Colonic Epithelial Cell Lines |year=2000 |last1=Toshina |first1=K. |last2=Hirata |first2=I. |last3=Maemura |first3=K. |last4=Sasaki |first4=S. |last5=Murano |first5=M. |last6=Nitta |first6=M. |last7=Yamauchi |first7=H. |last8=Nishikawa |first8=T. |last9=Hamamoto |first9=N. |last10=Katsu |first10=K. |journal=Scandinavian Journal of Immunology |volume=52 |issue=6 |pages=570–5 |pmid=11119262|display-authors=8 }}
* {{cite journal |doi=10.1023/A:1018825902055 |year=1997 |last1=Tari |first1=Akira |last2=Hamada |first2=Masanori |last3=Kamiyasu |first3=Toshiki |last4=Sumii |first4=Koji |last5=Haruma |first5=Ken |last6=Inoue |first6=Masaki |last7=Kishimoto |first7=Shinya |last8=Kajiyama |first8=Goro |last9=Walsh |first9=John H. |journal=Digestive Diseases and Sciences |volume=42 |issue=8 |pages=1741–6 |pmid=9286243 |title=Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients }}
* {{cite journal |doi=10.1007/BF02367786 |title=A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease |year=1995 |last1=Ching |first1=C. K. |last2=Lam |first2=S. K. |journal=Journal of Gastroenterology |volume=30 |issue=5 |pages=607–14 |pmid=8574332}}

{{Drugs for peptic ulcer and GORD}}
{{Prostaglandins}}
{{Prostanoidergics}}

[[Category:Prostaglandins]]
[[Category:Phenol ethers]]
[[Category:Methyl esters]]


{{gastrointestinal-drug-stub}}